Hans Gelderblom, MD, PhD, discusses the correlation between the overall response rate by Tumor Volume Score and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.
Hans Gelderblom, MD, PhD, professor of medical oncology at Leiden University Medical Centre, discusses the correlation between the overall response rate by Tumor Volume Score (TVS) and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.
In the phase III ENLIVEN trial, there was a 39% response rate by RECIST criteria in patients randomized to pexidartinib. However, these patients also had a 56% response rate by TVS criteria, says Gelderblom.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More